New drug combo tested for Tough-to-Treat advanced cancers
NCT ID NCT04225117
Summary
This study is testing an experimental drug called enfortumab vedotin, alone and in combination with pembrolizumab, in people with advanced solid tumors that have spread or returned after standard treatments. It aims to see if the treatment can shrink tumors and control the disease, while monitoring side effects. The trial includes 329 adults with specific types of advanced breast, lung, head and neck, and stomach cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Oncology
Tucson, Arizona, 85711, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
Florida Cancer Specialists
Tallahassee, Florida, 32308, United States
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Gettysburg Cancer Center
Gettysburg, Pennsylvania, 17375, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Indiana University Cancer Center
Indianapolis, Indiana, 46202, United States
-
Mary Crowley Research Center
Dallas, Texas, 75230, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
New York University Langone Health
New York, New York, 10016, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Northwestern University Medical Center
Chicago, Illinois, 60611, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Piedmont Hospital
Atlanta, Georgia, 30318, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Site CA15003
Ottawa, Ontario, K1H 8L6, Canada
-
Site JP81001
Kashiwa, Chiba, Japan
-
Site JP81002
Koto, Tokyo, Japan
-
Site JP81003
Chūō, Tokyo, Japan
-
Site JP81004
Nagoya, Aichi-ken, Japan
-
Site JP81005
Chuo-ku, Osaka, Japan
-
Site JP81006
Nakatogari, Shizuoka, Japan
-
Site JP81007
Ōsaka-sayama, Osaka, Japan
-
Site JP81010
Okayama, Japan
-
Site JP81011
Kitaadachi-Gun, Saitama, Japan
-
University of California - San Francisco
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Kansas
Fairway, Kansas, 66205, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Texas
Houston, Texas, 77030, United States
-
Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.